OPCH — Option Care Health, Inc.

Summary of Option Care Health Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $1.4 billion, up 2% year-over-year and 7% sequentially.
• Adjusted EBITDA: $117.5 million, an increase of 3% year-over-year and 12% sequentially.
• Adjusted EPS: $0.45, up $0.04 from the previous year, benefiting from share repurchases.
• Operating Cash Flow: Strong at $184 million, supported by working capital initiatives.
• Net Debt Leverage Ratio: 2.1x.
• Stock Buyback: $150 million repurchased, reducing remaining authorization to $525 million.

2. Strategic Updates and Business Highlights

• Acute Therapy Portfolio: High single-digit organic growth, with strong performance across all therapeutic categories.
• Chronic Therapy Portfolio: Stabilization in the CID segment, with sequential growth in IG neuro and rare orphan therapies.
• Expansion: Added five new ambulatory infusion clinics, with a 20% year-over-year increase in visits.
• Technology Investments: Focus on AI and digital tools to enhance operational efficiency and patient experience.
• Recognition: Ranked 15th on TIME's World's Most Impactful Companies of 2026 list.

3. Forward Guidance and Outlook

• Full-Year Revenue Guidance: Unchanged at $5.675 billion to $5.775 billion.
• Adjusted EBITDA Guidance: Narrowed to $480 million to $495 million.
• Adjusted EPS Guidance: Adjusted to a range of $1.85 to $1.92.
• Q3 Expectations: Low to mid-single-digit sequential revenue growth and mid-single-digit EBITDA growth anticipated.

4. Bad News, Challenges, or Points of Concern

• CID Portfolio Headwinds: Expected year-over-year revenue headwinds of approximately 600 basis points and gross profit headwinds of $55 million.
• Competitive Pressures: Ongoing challenges from white-bagging practices by PBMs affecting high-cost therapies.
• Market Dynamics: Uncertainty regarding formulary changes and the impact of new therapies entering the market.
• Satisfaction with Performance: Management expressed that while results were positive, they are not satisfied and see significant room for improvement.

5. Notable Q&A Insights

• Revenue Mix and Margins: Discussion on how the mix of chronic versus acute therapies could impact margins, with chronic therapies generally being more expensive but with lower margins.
• Commercial Initiatives: Updates on the effectiveness of realigning commercial resources and enhancing market strategies, with expectations for improved productivity in the second half of 2026.
• Long-term Growth Outlook: Management remains optimistic about the long-term growth potential of the chronic home infusion market, expecting to grow at or above market rates despite current challenges.
• Impact of Medicare Changes: Management noted that proposed Medicare coverage expansions for home infusion pumps may offer opportunities, though the immediate impact is expected to be limited due to the narrow scope of therapies involved.

This summary captures the essential details from the earnings call, highlighting both the positive developments and the challenges faced by Option Care Health.